{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:24:21Z","timestamp":1789208661611,"version":"build-2803163510"},"reference-count":186,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Androgen deprivation therapy (ADT) is commonly utilized in the management of both localized and advanced adenocarcinoma of the prostate. The use of ADT is associated with several adverse events, physical changes, and development of medical comorbidities\/mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>The current article reviews known adverse events associated with ADT as well as treatment options, where available. Current recommendations and guidelines are cited for ongoing monitoring of patients receiving ADT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A PubMed search of topics relating to ADT and adverse outcomes was performed, with select articles highlighted and reviewed based on level of evidence and overall contribution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome Measures<\/jats:title><jats:p>Reported outcomes of studies detailing adverse effects of ADT were reviewed and discussed. Where available, randomized trials and meta-analyses were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ADT may result in several adverse events including decreased libido, erectile dysfunction, vasomotor symptoms, cognitive, psychological and quality of life impairments, weight gain, sarcopenia, increased adiposity, gynecomastia, reduced penile\/testicular size, hair changes, periodontal disease, osteoporosis, increased fracture risk, diabetes and insulin resistance, hyperlipidemia, and anemia. The definitive impact of ADT on lipid profiles, cardiovascular morbidity\/mortality, and all-cause mortality is currently unknown with available data. Treatment options to reduce ADT-related adverse events include changing to an intermittent treatment schedule, biophysical therapy, counseling, and pharmacotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients treated with ADT are at increased risk of several adverse events and should be routinely monitored for the development of potentially significant morbidity\/mortality. Where appropriate, physicians should reduce known risk factors and counsel patients as to known risks and benefits of therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jsm.12036","type":"journal-article","created":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T16:47:29Z","timestamp":1360169249000},"page":"84-101","source":"Crossref","is-referenced-by-count":29,"title":["Androgen Deprivation Therapy Impact on Quality of Life and Cardiovascular Health, Monitoring Therapeutic Replacement"],"prefix":"10.1093","volume":"10","author":[{"given":"Landon W.","family":"Trost","sequence":"first","affiliation":[{"name":"Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ege","family":"Serefoglu","sequence":"additional","affiliation":[{"name":"Tulane University, Urology , New Orleans, LA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Gokce","sequence":"additional","affiliation":[{"name":"Tulane University, Urology , New Orleans, LA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Linder","sequence":"additional","affiliation":[{"name":"Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alton O.","family":"Sartor","sequence":"additional","affiliation":[{"name":"Tulane University, Urology , New Orleans, LA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[{"name":"Tulane University, Urology , New Orleans, LA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,2,1]]},"reference":[{"key":"2023012308004532500_bb0010","volume-title":"SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations), National Cancer Institute","author":"Howlader"},{"key":"2023012308004532500_bb0015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"2023012308004532500_bb0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-4295(02)01677-1","article-title":"Critical evaluation of hormonal therapy for carcinoma of the prostate","volume":"60","author":"Chodak","year":"2002","journal-title":"Urology"},{"key":"2023012308004532500_bb0025","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","article-title":"Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma","volume":"103","author":"Shahinian","year":"2005","journal-title":"Cancer"},{"key":"2023012308004532500_bb0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/95.13.981","article-title":"National practice patterns and time trends in androgen ablation for localized prostate cancer","volume":"95","author":"Cooperberg","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2023012308004532500_bb0035","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1056\/NEJMsa0910784","article-title":"Reimbursement policy and androgen-deprivation therapy for prostate cancer","volume":"363","author":"Shahinian","year":"2010","journal-title":"N Engl J Med"},{"key":"2023012308004532500_bb0040","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2007-2595","article-title":"Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis","volume":"93","author":"Shahani","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5694\/j.1326-5377.2006.tb00180.x","article-title":"Maintaining bone health in patients with prostate cancer","volume":"184","author":"Holmes-Walker","year":"2006","journal-title":"Med J Aust"},{"key":"2023012308004532500_bb0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","article-title":"Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy","volume":"194","author":"Grossmann","year":"2011","journal-title":"Med J Aust"},{"key":"2023012308004532500_bb0055","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"key":"2023012308004532500_bb0060","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1743-6109.2011.02233.x","article-title":"Is testosterone a friend or a foe of the prostate?","volume":"8","author":"Jannini","year":"2011","journal-title":"J Sex Med"},{"key":"2023012308004532500_bb0065","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2001.19.17.3750","article-title":"Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study","volume":"19","author":"Potosky","year":"2001","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0070","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.juro.2012.01.080","article-title":"The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: Observations from a prospective study in men undergoing intermittent androgen suppression","volume":"187","author":"Ng","year":"2012","journal-title":"J Urol"},{"key":"2023012308004532500_bb0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1054\/bjoc.1999.0916","article-title":"Prostate cancer treated by anti-androgens: Is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer","volume":"82","author":"Schroder","year":"2000","journal-title":"Br J Cancer"},{"key":"2023012308004532500_bb0080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1464-410X.2004.04763.x","article-title":"Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial","volume":"93","author":"Green","year":"2004","journal-title":"BJU Int"},{"issue":"1 suppl","key":"2023012308004532500_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000072488","article-title":"Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group","volume":"65","author":"Calais da Silva","year":"2003","journal-title":"Oncology"},{"key":"2023012308004532500_bb0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.urology.2004.03.032","article-title":"Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multicenter study","volume":"64","author":"Sato","year":"2004","journal-title":"Urology"},{"key":"2023012308004532500_bb0095","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.juro.2008.06.017","article-title":"Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer","volume":"180","author":"Gulley","year":"2008","journal-title":"J Urol"},{"key":"2023012308004532500_bb0100","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.juro.2008.06.029","article-title":"Testosterone recovery after prolonged androgen suppression in patients with prostate cancer","volume":"180","author":"Yoon","year":"2008","journal-title":"J Urol"},{"key":"2023012308004532500_bb0105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/j.1939-4640.1997.tb02435.x","article-title":"Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway","volume":"18","author":"Reilly","year":"1997","journal-title":"J Androl"},{"key":"2023012308004532500_bb0110","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.juro.2007.08.007","article-title":"Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer","volume":"178","author":"Teloken","year":"2007","journal-title":"J Urol"},{"key":"2023012308004532500_bb0115","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)65973-3","article-title":"Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate","volume":"166","author":"Spetz","year":"2001","journal-title":"J Urol"},{"key":"2023012308004532500_bb0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00042307-200405000-00007","article-title":"Complications of androgen deprivation therapy for prostate cancer","volume":"14","author":"Holzbeierlein","year":"2004","journal-title":"Curr Opin Urol"},{"key":"2023012308004532500_bb0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1557988306294162","article-title":"Physiology and endocrinology of hot flashes in prostate cancer","volume":"1","author":"Engstrom","year":"2007","journal-title":"Am J Mens Health"},{"key":"2023012308004532500_bb0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.urology.2008.09.013","article-title":"Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer","volume":"73","author":"Sakai","year":"2009","journal-title":"Urology"},{"key":"2023012308004532500_bb0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/pon.1401","article-title":"Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer","volume":"18","author":"Cherrier","year":"2009","journal-title":"Psychooncology"},{"key":"2023012308004532500_bb0140","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1200\/JCO.2010.30.8742","article-title":"Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer","volume":"28","author":"Alibhai","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0145","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/01.ju.0000091640.59812.83","article-title":"The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer","volume":"170","author":"Cherrier","year":"2003","journal-title":"J Urol"},{"key":"2023012308004532500_bb0150","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cncr.20962","article-title":"Estradiol and cognition during androgen deprivation in men with prostate carcinoma","volume":"103","author":"Salminen","year":"2005","journal-title":"Cancer"},{"key":"2023012308004532500_bb0155","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bjc.6601235","article-title":"Androgen deprivation and cognition in prostate cancer","volume":"89","author":"Salminen","year":"2003","journal-title":"Br J Cancer"},{"key":"2023012308004532500_bb0160","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1023\/A:1008318932641","article-title":"Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum","volume":"11","author":"Stone","year":"2000","journal-title":"Ann Oncol"},{"key":"2023012308004532500_bb0165","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/annonc\/mdr447","article-title":"Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy","volume":"23","author":"Storey","year":"2012","journal-title":"Ann Oncol"},{"key":"2023012308004532500_bb0170","first-page":"2547","article-title":"How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?","volume":"12","author":"Choo","year":"2005","journal-title":"Can J Urol"},{"key":"2023012308004532500_bb0175","article-title":"Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy(,)","author":"Saini","year":"2011","journal-title":"Urol Oncol"},{"key":"2023012308004532500_bb0180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.radonc.2010.12.006","article-title":"Depression related to (neo)adjuvant hormonal therapy for prostate cancer","volume":"98","author":"van Tol-Geerdink","year":"2011","journal-title":"Radiother Oncol"},{"key":"2023012308004532500_bb0185","first-page":"4249","article-title":"Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer","volume":"15","author":"DiBlasio","year":"2008","journal-title":"Can J Urol"},{"key":"2023012308004532500_bb0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/07347332.2011.651261","article-title":"Do patient-reported androgen-deprivation therapy side effects predict anxiety and depression among prostate cancer patients undergoing radiotherapy? Implications for psychosocial therapy interventions","volume":"30","author":"Sharpley","year":"2012","journal-title":"J Psychosoc Oncol"},{"key":"2023012308004532500_bb0195","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/cncr.26477","article-title":"Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer","volume":"118","author":"Timilshina","year":"2012","journal-title":"Cancer"},{"key":"2023012308004532500_bb0200","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol"},{"key":"2023012308004532500_bb0205","doi-asserted-by":"crossref","first-page":"b4817","DOI":"10.1136\/bmj.b4817","article-title":"Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study","volume":"339","author":"Smith","year":"2009","journal-title":"BMJ"},{"key":"2023012308004532500_bb0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cncr.10656","article-title":"The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma","volume":"95","author":"Fowler","year":"2002","journal-title":"Cancer"},{"key":"2023012308004532500_bb0215","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1464-410X.2002.02917.x","article-title":"Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: A randomized controlled trial","volume":"90","author":"Green","year":"2002","journal-title":"BJU Int"},{"key":"2023012308004532500_bb0220","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1532-5415.2005.00567.x","article-title":"Quality of life in prostate cancer patients taking androgen deprivation therapy","volume":"54","author":"Dacal","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"2023012308004532500_bb0225","first-page":"465","article-title":"Risk of the \u201candrogen deprivation syndrome\u201d in men receiving androgen deprivation for prostate cancer","volume":"166","author":"Shahinian","year":"2006","journal-title":"Arch Intern Med"},{"key":"2023012308004532500_bb0230","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2522\/ptj.20060302","article-title":"Physical function in men with prostate cancer on androgen deprivation therapy","volume":"87","author":"Clay","year":"2007","journal-title":"Phys Ther"},{"key":"2023012308004532500_bb0235","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"2023012308004532500_bb0240","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"63","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"2023012308004532500_bb0245","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0250","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0255","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2010.03942.x","article-title":"Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy","volume":"74","author":"Hamilton","year":"2011","journal-title":"Clin Endocrinol"},{"key":"2023012308004532500_bb0260","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11764-009-0114-1","article-title":"The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis","volume":"4","author":"Haseen","year":"2010","journal-title":"J Cancer Surviv"},{"key":"2023012308004532500_bb0265","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/pcan.2008.51","article-title":"Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation","volume":"12","author":"Galvao","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2023012308004532500_bb0270","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000082195","article-title":"Improved physical performance in older adults undertaking a short-term programme of high-velocity resistance training","volume":"51","author":"Henwood","year":"2005","journal-title":"Gerontology"},{"key":"2023012308004532500_bb0275","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1475-097X.2006.00695.x","article-title":"Short-term resistance training and the older adult: The effect of varied programmes for the enhancement of muscle strength and functional performance","volume":"26","author":"Henwood","year":"2006","journal-title":"Clin Physiol Funct Imaging"},{"key":"2023012308004532500_bb0280","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpainsymman.2011.03.006","article-title":"Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: A systematic review","volume":"43","author":"Keogh","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"2023012308004532500_bb0285","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0090-4295(01)01237-7","article-title":"Antiandrogen monotherapy: A new form of treatment for patients with prostate cancer","volume":"58","author":"Kolvenbag","year":"2001","journal-title":"Urology"},{"key":"2023012308004532500_bb0290","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1158\/1940-6207.CAPR-08-0205","article-title":"Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies","volume":"2","author":"Zanardi","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"2023012308004532500_bb0295","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1586\/14737140.7.12.1773","article-title":"Treatment of bicalutamide-induced breast events","volume":"7","author":"Sieber","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"2023012308004532500_bb0300","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2006.08.043","article-title":"Antiandrogens in the treatment of prostate cancer","volume":"51","author":"Wirth","year":"2007","journal-title":"Eur Urol"},{"key":"2023012308004532500_bb0305","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","article-title":"Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup","volume":"164","author":"Iversen","year":"2000","journal-title":"J Urol"},{"key":"2023012308004532500_bb0310","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1111\/j.1743-6109.2011.02364.x","article-title":"The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: A single-center, prospective, open-label, observational study","volume":"8","author":"Park","year":"2011","journal-title":"J Sex Med"},{"key":"2023012308004532500_bb0315","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.juro.2006.08.113","article-title":"Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer","volume":"177","author":"Haliloglu","year":"2007","journal-title":"J Urol"},{"issue":"1 suppl","key":"2023012308004532500_bb0320","first-page":"S11","article-title":"Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer","volume":"11","author":"Huhtaniemi","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"2023012308004532500_bb0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","article-title":"Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity","volume":"61","author":"Higano","year":"2003","journal-title":"Urology"},{"key":"2023012308004532500_bb0330","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2006.10.067","article-title":"The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer","volume":"177","author":"Famili","year":"2007","journal-title":"J Urol"},{"key":"2023012308004532500_bb0335","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2008.08156.x","article-title":"Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer","volume":"103","author":"Panju","year":"2009","journal-title":"BJU Int"},{"key":"2023012308004532500_bb0340","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1464-410X.2009.08483.x","article-title":"Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values","volume":"104","author":"Wadhwa","year":"2009","journal-title":"BJU Int"},{"key":"2023012308004532500_bb0345","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"key":"2023012308004532500_bb0350","first-page":"2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0355","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"2023012308004532500_bb0360","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0302-2838(03)00379-8","article-title":"Osteoporosis during continuous androgen deprivation: Influence of the modality and length of treatment","volume":"44","author":"Morote","year":"2003","journal-title":"Eur Urol"},{"key":"2023012308004532500_bb0365","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0370","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"key":"2023012308004532500_bb0375","doi-asserted-by":"crossref","first-page":"E456","DOI":"10.1210\/jc.2010-0902","article-title":"Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy","volume":"95","author":"Hamilton","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0380","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.urology.2004.07.019","article-title":"Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression","volume":"64","author":"Higano","year":"2004","journal-title":"Urology"},{"key":"2023012308004532500_bb0385","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1464-410X.2007.07163.x","article-title":"Fracture risk in Danish men with prostate cancer: A nationwide register study","volume":"100","author":"Abrahamsen","year":"2007","journal-title":"BJU Int"},{"key":"2023012308004532500_bb0390","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-004-1799-7","article-title":"Fracture risk in patients with prostate cancer on androgen deprivation therapy","volume":"16","author":"Lopez","year":"2005","journal-title":"Osteoporos Int"},{"key":"2023012308004532500_bb0395","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"2023012308004532500_bb0400","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0405","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J Urol"},{"key":"2023012308004532500_bb0410","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"2023012308004532500_bb0415","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/01.CIR.101.18.2149","article-title":"Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"2023012308004532500_bb0420","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.ATV.0000040224.49362.60","article-title":"In the elderly, interleukin-6 plasma levels and the -174G&gt;C polymorphism are associated with the development of cardiovascular disease","volume":"22","author":"Jenny","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023012308004532500_bb0425","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000026451","article-title":"Testosterone suppresses the response of the hypothalamic-pituitary-adrenal axis to interleukin-6","volume":"8","author":"Papadopoulos","year":"2000","journal-title":"Neuroimmunomodulation"},{"key":"2023012308004532500_bb0430","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1749-6632.1999.tb07667.x","article-title":"Sex hormones modulate inflammatory mediators produced by macrophages","volume":"876","author":"D\u2019Agostino","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"2023012308004532500_bb0435","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1677\/joe.1.06779","article-title":"Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency","volume":"189","author":"Corrales","year":"2006","journal-title":"J Endocrinol"},{"key":"2023012308004532500_bb0440","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2249.2003.02141.x","article-title":"Gonadotropin treatment restores in vitro interleukin-1beta and tumour necrosis factor-alpha production by stimulated peripheral blood mononuclear cells from patients with idiopathic hypogonadotropic hypogonadism","volume":"132","author":"Musabak","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"2023012308004532500_bb0445","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MED.0b013e32814db88c","article-title":"Androgen deprivation therapy for prostate cancer: New concepts and concerns","volume":"14","author":"Smith","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2023012308004532500_bb0450","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/CS20020209","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"Dockery","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"2023012308004532500_bb0455","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"2023012308004532500_bb0460","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0465","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2007.08.012","article-title":"Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer","volume":"70","author":"Lage","year":"2007","journal-title":"Urology"},{"key":"2023012308004532500_bb0470","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2023012308004532500_bb0475","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0480","article-title":"Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?","author":"Keating","year":"2012","journal-title":"Eur Urol"},{"key":"2023012308004532500_bb0485","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13685530701653538","article-title":"Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes","volume":"10","author":"Haidar","year":"2007","journal-title":"Aging Male"},{"key":"2023012308004532500_bb0490","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/archinte.167.6.612","article-title":"Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer","volume":"167","author":"Basaria","year":"2007","journal-title":"Arch Intern Med"},{"key":"2023012308004532500_bb0495","first-page":"1610","article-title":"Relationship of sex hormones to lipids and lipoproteins in nondiabetic men","volume":"77","author":"Haffner","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0500","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2003-031069","article-title":"The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men","volume":"89","author":"Malkin","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0505","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijir.3901471","article-title":"Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy","volume":"18","author":"Braga-Basaria","year":"2006","journal-title":"Int J Impot Res"},{"key":"2023012308004532500_bb0510","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2006.03.057","article-title":"The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters","volume":"176","author":"Yannucci","year":"2006","journal-title":"J Urol"},{"key":"2023012308004532500_bb0515","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1210\/jcem-66-2-314","article-title":"Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: Effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide","volume":"66","author":"Moorjani","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0520","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0525","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1210\/jc.2004-1158","article-title":"Endogenous sex hormones and metabolic syndrome in aging men","volume":"90","author":"Muller","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0530","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","article-title":"Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men","volume":"27","author":"Laaksonen","year":"2004","journal-title":"Diabetes Care"},{"key":"2023012308004532500_bb0535","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00059-004-2634-9","article-title":"Inflammation and atherosclerosis","volume":"29","author":"Steffens","year":"2004","journal-title":"Herz"},{"key":"2023012308004532500_bb0540","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1161\/01.CIR.0000148821.97162.5E","article-title":"Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study","volume":"110","author":"Vita","year":"2004","journal-title":"Circulation"},{"key":"2023012308004532500_bb0545","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0550","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.23440","article-title":"Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome","volume":"112","author":"Smith","year":"2008","journal-title":"Cancer"},{"key":"2023012308004532500_bb0555","first-page":"1757","article-title":"Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement","volume":"23","author":"Bogdanos","year":"2003","journal-title":"Anticancer Res"},{"key":"2023012308004532500_bb0560","first-page":"383","article-title":"Anemia in patients on combined androgen block therapy for prostate cancer","volume":"6","author":"Qian","year":"2004","journal-title":"Asian J Androl"},{"key":"2023012308004532500_bb0565","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/13685530802172438","article-title":"Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: A retrospective chart review","volume":"11","author":"Curtis","year":"2008","journal-title":"Aging Male"},{"key":"2023012308004532500_bb0570","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1464-410X.1997.00234.x","article-title":"Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade","volume":"79","author":"Strum","year":"1997","journal-title":"Br J Urol"},{"key":"2023012308004532500_bb0575","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"2023012308004532500_bb0580","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0585","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0590","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0595","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1464-410X.2011.10459.x","article-title":"Hormone therapy for prostate cancer and the risk of stroke: A 5-year follow-up study","volume":"109","author":"Chung","year":"2012","journal-title":"BJU Int"},{"key":"2023012308004532500_bb0600","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"2023012308004532500_bb0605","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2023012308004532500_bb0610","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D\u2019Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0615","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","article-title":"Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer","volume":"60","author":"Azoulay","year":"2011","journal-title":"Eur Urol"},{"key":"2023012308004532500_bb0620","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"2023012308004532500_bb0625","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1180::AID-CNCR18>3.0.CO;2-1","article-title":"Cause of death in men diagnosed with prostate carcinoma","volume":"83","author":"Satariano","year":"1998","journal-title":"Cancer"},{"key":"2023012308004532500_bb0630","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.ju.0000127740.96006.1a","article-title":"Changing patterns in competing causes of death in men with prostate cancer: A population based study","volume":"171","author":"Lu-Yao","year":"2004","journal-title":"J Urol"},{"key":"2023012308004532500_bb0635","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"2023012308004532500_bb0640","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2012.11120.x","article-title":"Intermittent hormonal therapy in the treatment of metastatic prostate cancer: A randomized trial","volume":"110","author":"Mottet","year":"2012","journal-title":"BJU Int"},{"key":"2023012308004532500_bb0645","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group","volume":"55","author":"Calais da Silva","year":"2009","journal-title":"Eur Urol"},{"key":"2023012308004532500_bb0650","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2011.38.3745","article-title":"Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer","volume":"30","author":"Yu","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0655","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","article-title":"Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature","volume":"57","author":"Abrahamsson","year":"2010","journal-title":"Eur Urol"},{"issue":"Suppl","key":"2023012308004532500_bb0660","article-title":"A phase III randomized trial of intermittent vs. continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7\/SWOG JPR.7\/CTSU JPR.7\/ UK Intercontinental Trial CRUKE\/01\/013)","author":"Crook","year":"2011","journal-title":"ASCO Annual Meeting: J Clin Oncol"},{"key":"2023012308004532500_bb0665","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jnci\/djm023","article-title":"Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial","volume":"99","author":"Moinpour","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2023012308004532500_bb0670","article-title":"Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer","author":"Langenhuijsen","year":"2011","journal-title":"Urol Oncol"},{"key":"2023012308004532500_bb0675","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/cncr.23473","article-title":"Antiandrogen withdrawal in castrate-refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9426)","volume":"112","author":"Sartor","year":"2008","journal-title":"Cancer"},{"key":"2023012308004532500_bb0680","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","article-title":"Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial","volume":"28","author":"Galvao","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0685","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMcp0707217","article-title":"Clinical practice. Osteoporosis in men","volume":"358","author":"Ebeling","year":"2008","journal-title":"N Engl J Med"},{"key":"2023012308004532500_bb0690","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1249\/01.mss.0000233803.48691.8b","article-title":"Resistance training and reduction of treatment side effects in prostate cancer patients","volume":"38","author":"Galvao","year":"2006","journal-title":"Med Sci Sports Exerc"},{"key":"2023012308004532500_bb0695","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","article-title":"Resistance exercise in men receiving androgen deprivation therapy for prostate cancer","volume":"21","author":"Segal","year":"2003","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0700","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1007\/s00520-011-1331-5","article-title":"Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer","volume":"20","author":"Davison","year":"2012","journal-title":"Support Care Cancer"},{"key":"2023012308004532500_bb0705","article-title":"Guidelines for the prevention of osteoporosis for men with prostate cancer on hormone therapy","author":"Agency BC","year":"2008"},{"key":"2023012308004532500_bb0710","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","article-title":"Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older","volume":"337","author":"Dawson-Hughes","year":"1997","journal-title":"N Engl J Med"},{"key":"2023012308004532500_bb0715","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.326.7387.469","article-title":"Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial","volume":"326","author":"Trivedi","year":"2003","journal-title":"BMJ"},{"key":"2023012308004532500_bb0720","article-title":"NCCN clinical practice guidelines in oncology: Prostate Cancer. V3.2012.","author":"Network NCC","year":"2012"},{"key":"2023012308004532500_bb0725","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/01.ju.0000130508.61020.66","article-title":"Osteoporosis and spinal fractures in men with prostate cancer: Risk factors and effects of androgen deprivation therapy","volume":"172","author":"Diamond","year":"2004","journal-title":"J Urol"},{"key":"2023012308004532500_bb0730","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2008.09.004","article-title":"Management of complications of androgen deprivation therapy in the older man","volume":"70","author":"Mohile","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"2023012308004532500_bb0735","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes","volume":"331","author":"Loprinzi","year":"1994","journal-title":"N Engl J Med"},{"key":"2023012308004532500_bb0740","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/01.ju.0000165570.28635.4b","article-title":"Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer","volume":"174","author":"Langenstroer","year":"2005","journal-title":"J Urol"},{"key":"2023012308004532500_bb0745","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: A double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"key":"2023012308004532500_bb0750","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007611-199904000-00013","article-title":"Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes","volume":"92","author":"Sartor","year":"1999","journal-title":"South Med J"},{"key":"2023012308004532500_bb0755","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0885-3924(03)00043-5","article-title":"Rapid progression of advanced \u201chormone-resistant\u201d prostate cancer during palliative treatment with progestins for cancer cachexia","volume":"25","author":"Tassinari","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"2023012308004532500_bb0760","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0090-4295(92)90264-W","article-title":"Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone","volume":"39","author":"Atala","year":"1992","journal-title":"Urology"},{"key":"2023012308004532500_bb0765","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0090-4295(99)00370-2","article-title":"Transdermal estrogen in the treatment of hot flushes in men with prostate cancer","volume":"55","author":"Gerber","year":"2000","journal-title":"Urology"},{"key":"2023012308004532500_bb0770","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0090-4295(92)90401-H","article-title":"Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer","volume":"40","author":"Miller","year":"1992","journal-title":"Urology"},{"key":"2023012308004532500_bb0775","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/gme.0b013e31802e7f22","article-title":"The variable response of women with menopausal hot flashes when treated with sertraline","volume":"14","author":"Kerwin","year":"2007","journal-title":"Menopause"},{"key":"2023012308004532500_bb0780","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/01.AOG.0000258278.73505.fa","article-title":"Ineffectiveness of sertraline for treatment of menopausal hot flushes: A randomized controlled trial","volume":"109","author":"Grady","year":"2007","journal-title":"Obstet Gynecol"},{"key":"2023012308004532500_bb0785","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","article-title":"Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: A randomized, double-blind, placebo-controlled trial","volume":"29","author":"Boekhout","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0790","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00005392-199907000-00024","article-title":"Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer","volume":"162","author":"Quella","year":"1999","journal-title":"J Urol"},{"key":"2023012308004532500_bb0795","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial","volume":"356","author":"Loprinzi","year":"2000","journal-title":"Lancet"},{"key":"2023012308004532500_bb0800","first-page":"128","article-title":"Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation Study-NCCTG Trial N00CB","volume":"8","author":"Moraska","year":"2010","journal-title":"J Support Oncol"},{"key":"2023012308004532500_bb0805","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","article-title":"Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial","volume":"366","author":"Pandya","year":"2005","journal-title":"Lancet"},{"key":"2023012308004532500_bb0810","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2006.07.5390","article-title":"Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5","volume":"25","author":"Loprinzi","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0815","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0090-4295(02)01641-2","article-title":"Complementary\/alternative therapies for reducing hot flashes in prostate cancer patients: Reevaluating the existing indirect data from studies of breast cancer and postmenopausal women","volume":"59","author":"Moyad","year":"2002","journal-title":"Urology"},{"key":"2023012308004532500_bb0820","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-137-10-200211190-00009","article-title":"Complementary and alternative medicine for menopausal symptoms: A review of randomized, controlled trials","volume":"137","author":"Kronenberg","year":"2002","journal-title":"Ann Intern Med"},{"key":"2023012308004532500_bb0825","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0029-7844(97)00597-8","article-title":"The effect of dietary soy supplementation on hot flushes","volume":"91","author":"Albertazzi","year":"1998","journal-title":"Obstet Gynecol"},{"key":"2023012308004532500_bb0830","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2310\/7200.2007.007","article-title":"Pilot evaluation of flaxseed for the management of hot flashes","volume":"5","author":"Pruthi","year":"2007","journal-title":"J Soc Integr Oncol"},{"key":"2023012308004532500_bb0835","author":"FRAX"},{"key":"2023012308004532500_bb0840","author":"National Osteoporosis Foundation"},{"key":"2023012308004532500_bb0845","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.juro.2010.02.022","article-title":"Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer","volume":"183","author":"Saylor","year":"2010","journal-title":"J Urol"},{"key":"2023012308004532500_bb0850","author":"National Osteoporosis Foundation Treatment Guidelines"},{"issue":"4","key":"2023012308004532500_bb0855","article-title":"Bisphosphonates for advanced prostate cancer","author":"Yuen","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2023012308004532500_bb0860","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"2023012308004532500_bb0865","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: A double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"2023012308004532500_bb0870","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023012308004532500_bb0875","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"2023012308004532500_bb0880","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.24404","article-title":"Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma","volume":"115","author":"Satoh","year":"2009","journal-title":"Cancer"},{"key":"2023012308004532500_bb0885","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1464-410X.2007.06853.x","article-title":"Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid","volume":"100","author":"Ryan","year":"2007","journal-title":"BJU Int"},{"key":"2023012308004532500_bb0890","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"2023012308004532500_bb0895","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1464-410X.2009.08622.x","article-title":"Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis","volume":"104","author":"Planas","year":"2009","journal-title":"BJU Int"},{"key":"2023012308004532500_bb0900","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1442-2042.2007.01911.x","article-title":"Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer","volume":"14","author":"Ishizaka","year":"2007","journal-title":"Int J Urol"},{"key":"2023012308004532500_bb0905","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.urology.2009.01.046","article-title":"Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy","volume":"73","author":"Izumi","year":"2009","journal-title":"Urology"},{"key":"2023012308004532500_bb0910","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"2023012308004532500_bb0915","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2023012308004532500_bb0920","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2008","journal-title":"J Urol"},{"key":"2023012308004532500_bb0925","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2009.05.019","article-title":"An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients","volume":"57","author":"Bedognetti","year":"2010","journal-title":"Eur Urol"},{"key":"2023012308004532500_bb0930","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clgc.2012.03.002","article-title":"A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia","volume":"10","author":"Serretta","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"2023012308004532500_bb0935","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","article-title":"Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia","volume":"60","author":"Tyrrell","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515304951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515304951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/Supplement_1\/84\/48805944\/jsm_10_supplement_1_84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/Supplement_1\/84\/48805944\/jsm_10_supplement_1_84.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T16:49:00Z","timestamp":1714927740000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/10\/Supplement_1\/84\/6994584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,1]]},"references-count":186,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2013,2,1]]},"published-print":{"date-parts":[[2013,2,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12036","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,2]]},"published":{"date-parts":[[2013,2,1]]}}}